PORTLAND, Maine, April 2, 2025 /PRNewswire/ -- MedRhythms today announced that Movive™, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), is now available for order within the U.S. Department of Veteran Affairs (VA) through the General Services Administration Multiple Award Schedule (GSA MAS), and also the Federal Supply Schedule (FSS)

Under his leadership, MedRhythms has raised over $60 million in capital, was recognized as an FDA breakthrough technology, and created high-paying jobs - all while advancing cutting-edge technology that serves people nationwide.

PORTLAND, Maine, March 6, 2025 /PRNewswire/ -- MedRhythms today announced that MR-005, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), has been listed as a Class II, Rx-only medical device with the U.S. Food and Drug Administration (FDA). The company unveiled the system's brand name: Movive™."Movive leverages the well-researched power of rhythmic auditory stimulation (RAS) for people with PD and is the second device to launch from MedRhythms' proprietary platform," said Brian Harris, Co-Founder and CEO of MedRhythms. "This is an exciting step for MedRhythms as we advance our mission to use music to address significant mobility challenges for people with neurologic injury and disease, including PD. We look forward to Movive's potential to support gait rehabilitation in PD, addressing a significant need."PD is the fastest growing neurodegenerative disease in the world. According to the Parkinson's Foundation , nearly one million Americans have PD, including 110,000 Veterans, making it the second most common neurodegenerative disease